De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Neuren Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Neuren Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 4.6% en 3.1% per jaar. De winst per aandeel zal naar verwachting groeien met 4.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 24.2% zijn.

Belangrijke informatie

4.6%

Groei van de winst

4.9%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	53.6%
Inkomstengroei	3.1%
Toekomstig rendement op eigen vermogen	24.2%
Dekking van analisten	Good
Laatst bijgewerkt	09 Sep 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

CHIA:NEU - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	187	118	100	80	5
12/31/2025	160	104	123	114	6
12/31/2024	123	80	-28	37	6
6/30/2024	193	117	119	120	N/A
3/31/2024	213	137	152	152	N/A
12/31/2023	232	157	185	185	N/A
9/30/2023	155	106	120	120	N/A
6/30/2023	78	55	54	54	N/A
3/31/2023	47	28	29	29	N/A
12/31/2022	15	0	4	4	N/A
9/30/2022	9	-3	-3	-3	N/A
6/30/2022	3	-7	-10	-10	N/A
3/31/2022	3	-7	-10	-10	N/A
12/31/2021	3	-8	-10	-10	N/A
9/30/2021	2	-10	-10	-10	N/A
6/30/2021	1	-12	-9	-9	N/A
3/31/2021	1	-11	-9	-9	N/A
12/31/2020	1	-9	-8	-8	N/A
9/30/2020	1	-8	-9	-9	N/A
6/30/2020	0	-8	-9	-9	N/A
3/31/2020	0	-9	-10	-10	N/A
12/31/2019	0	-11	-12	-12	N/A
9/30/2019	7	-6	-5	-5	N/A
6/30/2019	14	-1	2	2	N/A
3/31/2019	14	1	4	4	N/A
12/31/2018	14	3	6	6	N/A
9/30/2018	7	3	0	0	N/A
6/30/2018	1	3	-6	-6	N/A
3/31/2018	1	3	N/A	-6	N/A
12/31/2017	1	3	N/A	-6	N/A
9/30/2017	2	-2	N/A	-7	N/A
6/30/2017	3	-8	N/A	-8	N/A
3/31/2017	3	-10	N/A	-10	N/A
12/31/2016	3	-12	N/A	-12	N/A
9/30/2016	2	-14	N/A	-14	N/A
6/30/2016	0	-15	N/A	-17	N/A
3/31/2016	1	-14	N/A	-15	N/A
12/31/2015	2	-13	N/A	-13	N/A
9/30/2015	2	-11	N/A	-11	N/A
6/30/2015	3	-9	N/A	-8	N/A
3/31/2015	3	-9	N/A	-7	N/A
12/31/2014	3	-8	N/A	-6	N/A
9/30/2014	3	-10	N/A	-7	N/A
6/30/2014	3	-12	N/A	-7	N/A
3/31/2014	4	-11	N/A	-7	N/A
12/31/2013	5	-10	N/A	-7	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei NEU ( 4.6% per jaar) ligt boven de spaarquote ( 2.4% ).

Winst versus markt: De winst van NEU ( 4.6% per jaar) zal naar verwachting langzamer groeien dan de markt Australian ( 12.2% per jaar).

Hoge groeiwinsten: De winst van NEU zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van NEU ( 3.1% per jaar) zal naar verwachting langzamer groeien dan de markt Australian ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van NEU ( 3.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen NEU zal naar verwachting over 3 jaar hoog zijn ( 24.2 %)

Neuren Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Recent updates

First half 2024 earnings released: EPS: AU$0.063 (vs AU$0.38 in 1H 2023)

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 16%

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Investor sentiment improves as stock rises 38%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 25% undervalued after recent price drop

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 21% undervalued

Independent Non-Executive Director recently sold AU$15m worth of stock

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Independent Non-Executive Director recently bought AU$59k worth of stock

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome

High number of new directors

Independent Non-Executive Chairman recently bought AU$61k worth of stock

Neuren Pharmaceuticals Limited Receives Clear and Constructive Guidance from the Fda Office of Neuroscience in preIND Meetings for Phase 2 Clinical Trials of Nnz2591

Neuren Successfully Completes Drug Substance Manufacturing for NNZ-2591 Phase 2 Trials

New 90-day low: AU$1.26

Full year 2020 earnings released: AU$0.086 loss per share (vs AU$0.11 loss in FY 2019)

Independent Non-Executive Chairman recently bought AU$50k worth of stock

Neuren Pharmaceuticals Limited Adds Prader-Willi Syndrome to Pipeline with Compelling Results for NNZ-2591 in Pre-Clinical Model

European Commission Grants 3 NNZ-2591 Orphan Designations to Neuren Pharmaceuticals

New 90-day high: AU$1.40

Neuren Pharmaceuticals Limited Receives Approval for Final Stage of NNZ-2591 Clinical Trial

New 90-day high: AU$1.30

New 90-day low: AU$1.06

New 90-day low: AU$1.10

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven